Dynamic airway narrowing is a central hallmark of asthma and is caused by contraction of airway smooth muscle. The importance of the small GTPase RhoA in airway contraction has been increasingly recognized. However, the factors that regulate its activation state are not well understood. This proposal develops a research program focused on novel RhoA regulators developed in preliminary data. The central goal is to determine which pathways are most relevant to RhoA activation in asthmatic airway smooth muscle, for identification of novel therapeutic candidates.
In Aim 1, I pursue my recent finding that mice deficient for the scaffolding protein IQGAP1 have increased airway responsiveness and RhoA activation in airway smooth muscle. Our preliminary data suggest that IQGAP1 is required for recruitment of the RhoGAP p190A-RhoGAP to RhoA, thus normally facilitating inactivation of RhoA. I propose to test this model with biochemical studies aimed at disrupting interaction between IQGAP1 and p190A-RhoGAP and with mouse models of airway contraction involving both IQGAP1 and p190A-RhoGAP.
In Aim 2, I will determine the functional relevance of ArhGAP18, a RhoGAP that I have found in preliminary data to be highly expressed in airway smooth muscle. Furthermore, ArhGAP18 expression is decreased in airway biopsies from asthma patients compared with healthy controls. shRNA knockdown in airway smooth muscle cells and airway models with ArhGAP18 knockout mice will be used to query the relevance of this protein to the regulation of airway contractility.
In Aim 3, I focus on factors that intensify RhoA activation, known as guanine nucleotide exchange factors, because they could be targeted for therapeutic inhibition. In order to increase disease relevance, we will interrogate airway smooth muscle gene expression in patient airway biopsies and also perform functional testing of the effects of individual candidates on RhoA activation. These three aims are not co-dependent and will advance knowledge about a relatively unexplored pathway, RhoA activation, in airway smooth muscle pathobiology. The studies proposed are mechanistic and employ novel approaches that could have a significant impact on the development of novel therapies for asthma.

Public Health Relevance

A hallmark of asthma is airway smooth muscle contraction, with resulting airway narrowing that causes respiratory distress. Airway smooth muscle contractility is increased by the activation of the intracellular protein Rho. The current research seeks to understand the biology of regulation of Rho activation in airway smooth muscle in order to further understand the pathophysiology of asthma and to reveal potential targets for the development of molecular therapies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL131560-02
Application #
9266477
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Noel, Patricia
Project Start
2016-05-01
Project End
2021-04-30
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
2
Fiscal Year
2017
Total Cost
$379,051
Indirect Cost
$129,051
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Fong, Valerie; Hsu, Austin; Wu, Esther et al. (2018) Arhgef12 drives IL17A-induced airway contractility and airway hyperresponsiveness in mice. JCI Insight 3: